Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Toothpaste for Oral cGVHD
NCT06638879Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tacrolimus in chronic graft-versus-host disease (cGVHD), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Presence of mucosal ulcerations at 3 months. Started Sep 2024; status: completed.
02
Drugs
tacrolimus
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06638879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06638879.